Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

HSP nephritis

2,118 views

Published on

hsp nephritis

HSP nephritis

  1. 1. Henoch Schӧnlein Nephritis Ӧ
  2. 2. • Synonyms include anaphylactoid purpura, allergic vasculitis, leukocytoclastic vasculitis, and rheumatoid purpura.
  3. 3. • First description was by Heberden in 1806 • Schӧnlein first described the association of arthralgias and purpura, and he termed it ‘peliosis rheumatica’ in 1837. • Henoch (Schӧnlein’s student) described GI and renal manifestations in 1874 and 1899 respectively.
  4. 4. HSP in Children • Self limited • 20% long standing renal involvement. Of that 20%, 7% need HD • Children with renal involvement have a 35- 44% higher incidence of CKD in 24 year follow up. (Ronkainen J: The adult kidney 24 years after childhood HSP: retrospective cohort. Lancet 360: 666-670, 2002)
  5. 5. HSP in Adults • NO comparable incidence in adults • Overall 26% mortality in adults • Knowledge of natural history in adults is limited due to small series with short follow up. • More serious skin and joint involvement. • Renal disease is more frequent and more severe in adults, and more likely to progress. • Recurrence 10-40%, within 4 months. • Recurrence does not worsen prognosis.
  6. 6. Pathogenesis • Remains unknown; however, it is generally considered • Immune complex-mediated disease characterized by the presence of polymeric IgA1 (pIgA1)-containing immune complexes predominantly in dermal, gastrointestinal, and glomerular capillaries . • The pathognomonic granular IgA and C3 deposits in the mesangium are indistinguishable from those seen in IgA nephropathy
  7. 7. • C1GALT1 polymorphisms are associated with Henoch–Schönlein purpura nephritis • the G allele and GG genotype of 1365A/G were significantly increased in HSPN patients
  8. 8. Clinical feature • Rieu and Noel reported renal involvement in 33% of children and 63% of adults with HSP • A characteristic feature is hematuria- often is macroscopic but may be microscopic and either transient, persistent, or recurrent • Hematuria may accompany relapses of purpura or recur long after the extrarenal manifestations have resolved, often in association with upper respiratory infections • Usually, there is associated proteinuria of variable intensity, and the frequency of the nephrotic syndrome is also extremely variable. • Deterioration of GFR may occur, and azotemia or end-stage renal failure may ensue
  9. 9. Renal Involvement- Children • Only 1-5% progress to ESRD. • 10-50% of children get microscopic hematuria, mild GN, and proteinuria that resolves spontaneously. • Up to 33% recurrence in children, but symptoms are milder and shorter duration
  10. 10. Renal Involvement-Adults • 11% on HD • 10-30% ESRD at 15 years • 27% CrCl <50% • 50% persistent hematuria • 47% moderate proteinuria • 8% nephrotic range • 20% remission Evangeline, P: HSP in adults, Outcome and Prognosis factors, J Am Soc Nephrology 13:1271: 2002
  11. 11. Children versus Adults • 95 adults and 57 children, 5 year follow up • Crescents and nephrotic range proteinuria equal incidence • Residual CKD 31% in adults versus 24% children. • Adults 2x more likely to progress to HD/ESRD. (16 versus 7%) • Poor prognosis: >50% crescents, renal impairment at presentation, UP/C> 1.5 g/day, HTN Coppo R: Long term Prognosis of HSP nephritis in adults and children. Nephrol Dial Transplant 12: 2277-2283, 1997
  12. 12. Renal Transplant after HSP • 35% recurrence • 11% graft loss • Meulders et al
  13. 13. Diagnostic criteria Palpable purpura (mandatory) in the presence of at least one of the following four features: – Diffuse abdominal pain – Arthritis (acute) or arthralgia – Renal involvement (any haematuria and/or proteinuria) – Any biopsy showing predominant IgA deposition Ozen S et al Ann Rheu Dis 65:936-41, 2006 ,EULAR/PReS consensus criteria
  14. 14. What constitutes renal involvement? • Isolated Haematuria • Isolated Proteinuria • Nephrotic syndrome • Nephritic syndrome – Renal impairment – Hypertension Risk of long term renal impairment and duration of follow up recommended for Henoch-Schönlein purpura with normal or minimal urinary findings: a systematic review. Narchi H. Arch Dis Child 2005
  15. 15. What investigations if renal involvement? Primary Investigations U&E, HCO3, creatinine Albumin urine Protein:Creatinine urine dipstix and microscopy FBC Clotting screen Secondary Investigations Anti-streptococcal titre (ASOT) Antinuclear antibody (ANA) + dsDNA Antinuclear cytoplasmic antibody (ANCA) Complement – C3, C4 ESR CRP Renal ultrasound
  16. 16. HSP – Onset of nephritis Time of onset of urinary abnormalities after the diagnosis of HSP Weeks after HSP diagnosis 1 2 4 6 8 24 % 37 54 84 90 91 97 Narchi H Arch Dis Child 90:916-20, 2005
  17. 17. Indications for renal biopsy • Acute renal impairment/nephritic syndrome at presentation • Nephrotic syndrome with normal renal function persisting at 4 weeks • Nephrotic range proteinuria (urine protein/creatinine ratio, >250 mg/mmol) at 4–6 weeks (if not improving spontaneously) • Persistent proteinuria • urine protein/creatinine ratio >100 mg/mmol at >3 months particularly if diagnosis is not clear. Clinical practice: Diagnosis and management of Henoch–Schönlein purpura. McCarthy H & Tizard EJ. Eur J Pediatr (2010)
  18. 18. Henoch- Schönlein Nephritis histological classification – ISKDC Class Mesangial change Crescents Frequency % (n = 355) * I Minimal changes 8 II Pure mesangial proliferation 29 III a b focal diffuse mesangial proliferation mesangial proliferation <50% 43 IV a b focal diffuse mesangial proliferation mesangial proliferation 50 – 75% 12 V a b focal diffuse mesangial proliferation mesangial proliferation >75% 6 VI Membranoproliferative like glomerulonephritis 3 * Pooled data from Pathology of the Kidney, 6th Edition, Jennette et al. Philadelphia, Lippincott Williams & Wilkins, 2007.
  19. 19. Histology and the normal glomerulus
  20. 20. Normal glomerulus Moderate mesangial expansion – class 2 – ‘mild’. Mesangial proliferation and crescent formation Focal and segmental mesangial hypercellularity with associated capillary luminal leukocytes
  21. 21. • Immunofluorescence microscopy. There is granular staining for IgA in mesangial regions and segmentally along capillary walls. • which is often accompanied by C3, fibrinogen, and both light chains, and less frequently by IgG and/or IgM
  22. 22. • Electron microscopy. There are electron-dense deposits in the mesangium, and segmentally in subendothelial locations.
  23. 23. What treatments can be used for HSP Nephritis? • Immunosuppressants – Steroids • IV MP • po Prednisolone – Cyclophosphamide (CyP) – Ciclosporin – Plasma exchange – Rituximab? • ACEi
  24. 24. • No adequate evidence • No RCTs for treatment of HSP nephritis • The treatment of HSP nephritis is controversial, and recommendations are based on small, often uncontrolled series.
  25. 25. Current RHSC(G) guideline HSP Class Management I & II No immunosuppressant treatment routinely ACEi if persistent proteinuria III Pulse IV methylprednisolone 600mg/m2 for 3 days Oral prednisolone 60mg/m2 (max 60mg) for 1 month and taper Consider Cyclophosphamide 2.5mg/kg/day for 56 days ACEi if persistent proteinuria IV & V (VI) Pulse IV methylprednisolone 600mg/m2 for 3 days Oral prednisolone 60mg/m2 (max 60mg) for 1 month and taper Cyclophosphamide 2.5mg/kg/day for 56 days Consider Plasma exchange ACEi if persistent proteinuria
  26. 26. Will steroids prevent renal disease in HSP? • No! ChartapisakW, Opastirakul S, Willis NS, Craig JC, Hodson EM. ADC, 2008 and Cochrane review updated, 2010.
  27. 27. Will steroids improve outcome for acute mild renal symptoms? • RCT early steroid in HSP • Sub group analysis • 71 with renal symptoms in first month • More rapid resolution with steroids at 6 months – Ronkainen et al. J Ped 2006.
  28. 28. Recommended follow-up • BP & urine dipstix for – week 1-6 weekly – Week 7-24 monthly Narchi H Arch Dis Child 90:916-20, 2005
  29. 29. The adult kidney 24 years after childhood HSP: a retrospective cohort study. Clinical presentation at onset of Henoch - Schönlein purpura I no renal symptoms II proteinuria + haematuria, and no biopsy specimen or ISKDC biopsy grade I - II III renal symptoms > 1 month, nephritis or nephrosis, and ISKDC biopsy grade III or more Nephritis: haematuria and 2/3 symptoms: increase in serum creatinine, oliguria, hypertension. Nephrosis: proteinuria > 40 mg/m2/hr. Clinical outcome A healthy B minor urinary abnormalities (intermittent hypertension, proteinuria, haematuria) C active renal disease (hypertension, constant proteinuria) D end-stage renal disease (dialysis treatment or renal transplantation) Ronkainen et al. Lancet, 2002
  30. 30. The adult kidney 24 years after childhood HSP: a retrospective cohort study. Onset Grade Number of patients Good outcome A + B Poor Outcome C + D I 9 9 (100%) 0 II 18 16 (89%) 2 (11%) III 20 13 (65%) 7 (35%) • Clinical outcome after mean follow-up of 24·1 years, by symptoms at onset • Ronkainen et al. Lancet, 2002
  31. 31. Discuss with Nephrologist • Hypertension • Abnormal renal function • Macroscopic haematuria > 5 days • Persisting proteinuria
  32. 32. Summary • HSP is the commonest vasculitis of childhood • Renal involvement is frequent • Significant renal disease is less common but can develop up to 3 months from presentation • Early steroid therapy in HSP does not prevent nephritis • Treatment interventions for HSP nephritis are not well evidence based • Variations in long term outcomes may reflect changes in clinical practice over time • Prompt intervention in more severe nephritis with immunosuppression is still used • ACEi for persistent ‘chronic’ proteinuric nephropathy is recommended
  33. 33. • Thank you
  34. 34. Detection and referral of patients with Henoch–Schönlein purpura nephritis (adapted from local guidelines developed by Dr D Hothi and Bristol Paediatric Nephrologists). Tizard E J , Hamilton-Ayres M J J Arch Dis Child Educ Pract Ed 2008;93:1-8 Copyright © BMJ Publishing Group Ltd & Royal College of Paediatrics and Child Health. All rights reserved.

×